WHO Report on Cancer: setting priorities, investing wisely and providing care for all 2020, World Health Organization.

Stewart, B. W. & Wild, C. P. (2014) World Cancer Report 2014, International Agency for Research on Cancer, Lyon.

Nurgali, K. et al. Editorial: adverse effects of cancer chemotherapy: anything new to improve tolerance and reduce sequelae? Front. Pharmacol. 9, 245 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Cancer Research Institute 2020, Cancer vaccines: preventive, therapeutic, personalised.

Zepp, F. Principles of vaccination. Vaccine Design: Methods and Protocols: Volume 1: Vaccines for Human Diseases (S. Thomas), 57–84 (Springer, 2016).

Lin, C. L. & Kao, J. H. Hepatitis B: immunization and impact on natural history and cancer incidence. Gastroenterol. Clin. North Am. 49, 201–214 (2020).

Article  PubMed  Google Scholar 

Markowitz, L. E. & Unger, E. R. Human papillomavirus vaccination. N. Engl. J. Med. 388, 1790–1798 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Ahrends, T. et al. CD4+ T cell help confers a cytotoxic T cell effector program including coinhibitory receptor downregulation and increased tissue invasiveness. Immunity 47, 848–861.e5 (2017).

Article  CAS  PubMed  Google Scholar 

Wang, H. & Mooney, D. J. Biomaterial-assisted targeted modulation of immune cells in cancer treatment. Nat. Mater. 17, 761–772 (2018).

Article  CAS  PubMed  Google Scholar 

Hollingsworth, R. E. & Jansen, K. Turning the corner on therapeutic cancer vaccines. npj Vaccines. 4, 1–10 (2019).

Barnes, T. A. & Amir, E. HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer. Br. J. Cancer 117, 451–460 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Soysal, S. D. et al. Role of the tumor microenvironment in breast cancer. Pathobiology 82, 142–152 (2015).

Article  CAS  PubMed  Google Scholar 

Purcell, A. et al. More than one reason to rethink the use of peptides in vaccine design. Nat. Rev. Drug Discov. 6, 404–414 (2007).

Article  CAS  PubMed  Google Scholar 

Oyarzun, P. & Kobe, B. Computer-aided design of T-cell epitope-based vaccines: addressing population coverage. Int. J. Immunogenet. 42, 313–321 (2015).

Article  CAS  PubMed  Google Scholar 

Slingluff, C. L. Jr The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? Cancer J. 17, 343–350 (2011).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tanaka, Y., et al. TAS0314, a novel multi-epitope long peptide vaccine, showed synergistic antitumor immunity with PD-1/PD-L1 blockade in HLA-A*2402 mice. Sci. Rep. 12, 6082 (2020).

Article  Google Scholar 

Bijker, M. S. et al. CD8+ CTL priming by exact peptide epitopes in incomplete Freund’s adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J. Immunol. 179, 5033–5040 (2007).

Article  CAS  PubMed  Google Scholar 

Rabu, C., et al. Cancer vaccines: designing artificial synthetic long peptides to improve presentation of class I and class II T cell epitopes by dendritic cells. Oncoimmunology 8, e1560919 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Skwarczynski, M. & Toth, I. Peptide-based synthetic vaccines. Chem. Sci. 7, 842–854 (2016).

Article  CAS  PubMed  Google Scholar 

Sidney, J. et al. HLA class I supertypes: a revised and updated classification. BMC Immunol. 9, 1 (2008).

Article  PubMed  PubMed Central  Google Scholar 

Liu, J. et al. Recent advances in mRNA vaccine technology. Curr. Opin. Immunol. 65, 14–20 (2020).

Article  Google Scholar 

Stephens, A.J. et al. Beyond just peptide antigens: the complex world of peptide-based cancer vaccines. Front. Immunol. 12, 696791 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang, Y.S. et al. mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications. J. Biomed. Sci. 30, 84 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xie, C. et al. The advances of adjuvants in mRNA vaccines. npj Vaccines 8, 162 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144–150 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403, 632–644 (2024).

Article  CAS  PubMed  Google Scholar 

Barbier, A. J. et al. The clinical progress of mRNA vaccines and immunotherapies. Nat. Biotechnol. 40, 840–854 (2022).

Article  CAS  PubMed  Google Scholar 

Pardi, N. et al. Recent advances in mRNA vaccine technology. Curr. Opin. Immunol. 65, 14–20 (2020).

Article  CAS  PubMed  Google Scholar 

Li, Y., et al. mRNA vaccine in cancer therapy: current advance and future outlook. CTM 13, e1384 (2023)

CAS  PubMed  PubMed Central  Google Scholar 

Kenoosh, H. A., et al. Recent advances in mRNA-based vaccine for cancer therapy; bench to bedside. Cell Biochem. Funct. 42, e3954 (2024).

Article  CAS  PubMed  Google Scholar 

Woldemeskel, B. A., et al. CD4+ T cells from COVID-19 mRNA vaccine recipients recognize a conserved epitope present in diverse coronaviruses. J. Clin. Investig. 132, e156083 (2022).

Heitmann, J. S. et al. A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity. Nature 601, 617–622 (2022).

Article  CAS  PubMed  Google Scholar 

Tandler, C. et al. Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adults. IJID 139, 69–77 (2024).

CAS  PubMed  Google Scholar 

Kalita, P. & Tripathi, T. Methodological advances in the design of peptide-based vaccines. Drug Discov. Today 27, 1367–1380 (2022).

Article  CAS  PubMed  Google Scholar 

Sckisel, G. D. et al. Out-of-sequence signal 3 paralyses primary CD4+ T-cell-dependent immunity. Immunity 43, 240–250 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fukaya, T. et al. Analysis of DC functions using CD205-DTR knock-in mice. Dendritic Cell Protocols. Methods in Molecular Biology Segura, E. (eds), 291–308 (Springer, 2016).

Geng, J. et al. Selected HLA-B allotypes are resistant to inhibition or deficiency of the transporter associated with antigen processing (TAP). PLoS Pathog. 14, e1007171 (2018).

Article  PubMed  PubMed Central  Google Scholar 

den Brok, M. H. et al. Saponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formation. Nat. Commun. 7, 13324 (2016).

Article  Google Scholar 

Ahrends, T. et al. CD4+ T cell help create memory CD8+ T cells with innate and help-independent recall capacities. Nat. Commun. 10, 5531 (2019).

Ferris, S. T. et al. cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity. Nature 584, 624–629 (2020).

Noubade, R. et al. Beyond cDC1: emerging roles of DC crosstalk in cancer immunity. Front. Immunol. 10, 1014 (2019).

Article